Changchun Ling

Dr. Changchun Ling


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2020 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
YLYong Ling
Yong Ling
JLJi Liu
Ji Liu
JQJianqiang Qian
Jianqiang Qian
CMChi Meng
Chi Meng
JGJing Guo
Jing Guo
YZYanan Zhang
Yanan Zhang
Protein Kinase Inhibitors (PKIs) and Histone Deacetylase Inhibitors (HDACIs) are two important classes of anticancer agents and have provided a variety of small molecule drugs for the treatment of various types of human cancers. However, malignant tumors are of a multifactorial nature that can hardly be “cured” by targeting a single target, and treatment of cancers hence requires modulation of multiple biological targets to restore the physiological balance and generate sufficient therapeutic efficacy. Multi-target drugs have attracted great interest because of their advantages in the treatment of complex cancers by simultaneously targeting multiple signaling pathways and possibly leading to synergistic effects. Synergistic effects have been observed in the combination of kinase inhibitors, such as imatinib, dasatinib, or sorafenib, with an array of HDACIs including vorinostat, romidepsin, or panobinostat. A considerable number of multi-target agents based on PKIs and HDACIs have been developed. In this review, we summarize the recent literature on the development of multi-target kinase-HDAC inhibitors and provide our view on the challenges and future directions on this topic.

23 February 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
YMYu‐Shui Ma
Yu‐Shui Ma
TWTing‐Miao Wu
Ting‐Miao Wu
BQBin Qian
Bin Qian
YLYu‐Shan Liu
Yu‐Shan Liu
HDHua Ding
Hua Ding
DFDa Fu
Da Fu
Hepatocellular cancer (HCC) has been reported to belong to one of the highly vascularized solid tumours accompanied with angiogenesis of human umbilical vein endothelial cells (HUVECs). KDM5A, an attractive drug target, plays a critical role in diverse physiological processes. Thus, this study aims to investigate its role in angiogenesis and underlying mechanisms in HCC. ChIP‐qPCR was utilized to validate enrichment of H3K4me3 and KDM5A on the promotor region of miR‐433, while dual luciferase assay was carried out to confirm the targeting relationship between miR‐433 and FXYD3. Scratch assay, transwell assay, Edu assay, pseudo‐tube formation assay and mice with xenografted tumours were conducted to investigate the physiological function of KDM5A‐miR‐433‐FXYD3‐PI3K‐AKT axis in the progression of HCC after loss‐ and gain‐function assays. KDM5A p‐p85 and p‐AKT were highly expressed but miR‐433 was down‐regulated in HCC tissues and cell lines. Depletion of KDM5A led to reduced migrative, invasive and proliferative capacities in HCC cells, including growth and a lowered HUVEC angiogenic capacity in vitro. Furthermore, KDM5A suppressed the expression of miR‐433 by demethylating H3K4me3 on its promoterregion. miR‐433 negatively targeted FXYD3. Depleting miR‐433 or re‐expressing FXYD3 restores the reduced migrative, invasive and proliferative capacities, and lowers the HUVEC angiogenic capacity caused by silencing KDM5A. Therefore, KDM5A silencing significantly suppresses HCC tumorigenesis in vivo, accompanied with down‐regulated miR‐433 and up‐regulated FXYD3‐PI3K‐AKT axis in tumour tissues. Lastly, KDM5A activates the FXYD3‐PI3K‐AKT axis to enhance angiogenesis in HCC by suppressing miR‐433.

2 May 2023 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
JLJi Liu
Ji Liu
ZXZhongyuan Xu
Zhongyuan Xu
CMChi Meng
Chi Meng
SWSainaiwaiergul Wusiman
Sainaiwaiergul Wusiman
XXXudong Xie
Xudong Xie
YLYong Ling
Yong Ling

1 January 2023 in Theranostics
Verified
Journal Article
Open access
PDF file
ZXZhongyuan Xu
Zhongyuan Xu
JQJianqiang Qian
Jianqiang Qian
HWHongmei Wu
Hongmei Wu
CMChi Meng
Chi Meng
QDQian Ding
Qian Ding
YLYong Ling
Yong Ling
Rationale: Challenges such as developing a universal tumor-specific probe for tumor margin identification in diverse tumors with an easy-operative and fast-imaging pattern still exist. Hence, in the present study, a rapidly “off-on” near-infrared (NIR) fluorescent probe NBD with pH-activatable fluorescence and a large Stokes shift was constructed for spray mediated near-instant and precise clinical tumor margins identification.

18 January 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JMJiefei Miao
Jiefei Miao
CMChi Meng
Chi Meng
HWHongmei Wu
Hongmei Wu
WSWenpei Shan
Wenpei Shan
HWHaoran Wang
Haoran Wang
TYTao Yang
Tao Yang
A novel hybrid CHC was designed and synthesized by conjugating β-carboline with an important active fragment N-hydroxyacrylamide of histone deacetylase (HDAC) inhibitor by an amide linkage to enhance antitumor efficacy/potency or even block drug resistance. CHC displayed high antiproliferative effects against drug-sensitive SUMM-7721, Bel7402, Huh7, and HCT116 cells and drug-resistant Bel7402/5FU cells with IC50 values ranging from 1.84 to 3.27 μM, which were two-to four-fold lower than those of FDA-approved HDAC inhibitor SAHA. However, CHC had relatively weak effect on non-tumor hepatic LO2 cells. Furthermore, CHC exhibited selective HDAC1/6 inhibitory effects and simultaneously augmented the acetylated histone H3/H4 and α-tubulin, which may make a great contribution to their antiproliferative effects. In addition, CHC also electrostatically interacted with CT-DNA, exerted remarkable cellular apoptosis by regulating the expression of apoptosis-related proteins and DNA damage proteins in Bel7402/5FU cells, and significantly accumulated cancer cells at the G2/M phase of the cell cycle by suppressing CDK1 and cyclin B protein with greater potency than SAHA-treated groups. Finally, CHC displayed strong inhibitory potency to drug-resistant hepatic tumors in mice. Our designed and synthetic hybrid CHC could be further developed as a significant and selective anticancer agent to potentially treat drug-resistant hepatocellular carcinoma.

10 September 2023 in Analytica Chimica Acta
Verified
Journal Article
Closed access
CLChangchun Ling
Changchun Ling
TSTiantian Sun
Tiantian Sun
FCFang Chen
Fang Chen
HWHongmei Wu
Hongmei Wu
WTWeizhi Tao
Weizhi Tao
YZYanan Zhang
Yanan Zhang